问题 › 无法判断战略是否有效 › 专业服务
无法出错的战略无法检验,而专业服务机构撰写的多数战略都刻意写成无法出错。 专业服务机构在此面临特定困境——合伙人薪酬机制理性地奖励人们<em>不去</em>销售机构中最高利润的产品。在定价问题解决前,可计费利用率会因无人能解释的原因持续变动,而领先指标的争论仍停留在意见层面。
无法出错的战略无法检验,而专业服务机构撰写的多数战略都刻意写成无法出错。 专业服务机构在此面临特定困境——合伙人薪酬机制理性地奖励人们不去销售机构中最高利润的产品。在定价问题解决前,可计费利用率会因无人能解释的原因持续变动,而领先指标的争论仍停留在意见层面。
战略无法评估的常见原因是它从未以可能失败的形式陈述。提高每合伙人收入或改善合伙人杠杆等目标,不会产生与利用率、实现率或项目利润相矛盾的观察,因此无论管理合伙人每季度看到何种数字,战略都能无限存续。
可检验的战略会指明机制——合伙人薪酬的这一变化将在这一日期前产生可计费利用率或最高利润工作实现率的这一转变——以及表明机制不奏效的观察。后半部分将计划转化为机构可依据已有项目利润和闲置数据进行管理的对象。
另一常见原因是滞后。战略周期长于月度利用率报告,因此诚实的做法是提前识别领先指标,如闲置变动或项目组合早期变化,并在这些指标先于每合伙人收入移动前,明确其应读数。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 利用率和实现率报告显示活动稳定,但若数字持平或恶化,其中没有任何一行会与战略相矛盾。
✓ 每周或每月更新列出完成的提案、招聘或项目,却未将其中任何一项与项目利润或合伙人杠杆的必要变动相连。
✓ 合伙人与管理合伙人对战略是否有效得出不同结论,且无法通过指向相同的利用率、实现率或闲置数据来解决分歧。
通常会让情况更糟的做法。 增加更多利用率仪表板和实现率明细,这会提高数字数量,却未将其中任何一项与可能显示战略不奏效的陈述相连。
It is for you if you run or finance a professional services firm and the strategy has no failure condition written anywhere. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家专业服务机构. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Aldergate Partners, a sample company profile used for testing rather than a customer — $88M revenue, 310 people.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Align partner economics so selling an $85K diagnostic becomes as attractive as booking a $340K T&M engagement in the same quarter.
The leak it closes. Eliminates the $1.53M annual leakage where partners book $340K T&M instead of $85K diagnostic + $410K implementation, destroying $325K firm-level margin differential per converted engagement
The assumption it rests on. Partners accept 1.5× diagnostic credit and 10% implementation share rather than exiting — the engine put the probability at 0.75.
| Investment required | $180-240K |
| Expected return | 8.5-11.3× |
| Revenue, year 1 | $2.04M incremental diagnostic revenue + $5.3M implementation follow-on |
| Revenue, year 2 | $3.4M incremental diagnostic revenue + $8.8M implementation follow-on |
| Revenue, year 3 | $4.6M incremental diagnostic revenue + $11.9M implementation follow-on |
| Exit criteria | Terminate if 4 of 5 pilot partners refuse to sign by Month 4 OR if the $9.4M largest account fails to renew in Q3, triggering immediate reversal to legacy compensation model and diagnostic deprioritization |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 专有EFF方法, one of 29 engagements the platform runs. For 专业服务机构 it works through billable utilisation, realisation, revenue per partner and engagement gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
它所依赖的机制,而非它承诺的结果。结果滞后;机制提前移动,能更早告诉你因果主张是否成立。
在开始前决定,并与机制的自然周期绑定。事后决定会确保时间线被选为配合已出现的任何结果。
这通常表明战略不够具体,无法产生清晰检验。缩小范围,直到一个数字能解决争论。
Materially, yes. Partner compensation rationally pays people not to sell the highest-margin product in the firm — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are billable utilisation, realisation, revenue per partner, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on billable utilisation and realisation. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית